Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial

Abstract

Of 55 million deaths globally every year, about 30% are from cardiovascular diseases.¹ Of these, 40% to 50% are likely to be due to acute myocardial infarction (AMI).¹ Antiplatelet therapy,^2,3 thrombolytic therapy⁴ and angiotensin-converting enzyme inhibitors⁵ improve prognosis in ST-segment elevation AMI (STEMI). Primary percutaneous coronary intervention (PCI) offers benefits over thrombolytic therapy, but access to this procedure is limited.⁶ Advances in treatments are likely to have a greater public health and clinical impact if they are effective, safe, simple to administer, affordable, and applicable to a widely diverse spectrum of economic and health care settings.